Get the Stockscreener App
0.97
2.56%
-0.0255
After Hours:
.96
-0.01
-1.03%
Evogene Ltd stock is traded at $0.97, with a volume of 13,963.
It is down -2.56% in the last 24 hours and down -32.64% over the past month.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.
See More
Previous Close:
$0.9955
Open:
$0.9808
24h Volume:
13,963
Relative Volume:
0.65
Market Cap:
$7.14M
Revenue:
$5.64M
Net Income/Loss:
$-23.88M
P/E Ratio:
-1.8302
EPS:
-0.53
Net Cash Flow:
$-22.36M
1W Performance:
-3.96%
1M Performance:
-32.64%
6M Performance:
-54.67%
1Y Performance:
-85.84%
1-Day Range:
$0.95
$0.9836
1-Week Range:
$0.95
$1.08
52-Week Range:
$0.95
$8.996
Evogene Ltd Stock (EVGN) Company Profile
Compare EVGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
0.97 | 7.14M | 5.64M | -23.88M | -22.36M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-21 | Initiated | ROTH Capital | Buy |
| Jul-29-21 | Initiated | Aegis Capital | Buy |
| Dec-01-20 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-16-13 | Initiated | Oppenheimer | Outperform |
Evogene Ltd Stock (EVGN) Latest News
Evogene (NASDAQ:EVGN) Share Price Crosses Below 200-Day Moving Average – Should You Sell? - Defense World
Evogene (NASDAQ:EVGN) Coverage Initiated at StockNews.com - Defense World
Evogene stock hits 52-week low at $0.99 amid market challenges By Investing.com - Investing.com South Africa
Evogene Schedules Third Quarter 2024 Financial Results Release - marketscreener.com
Evogene stock hits 52-week low at $0.99 amid market challenges - Investing.com Australia
Biomica CEO Set to Engage in Panel Discussion at 8th Annual Euro - GuruFocus
Evogene (NASDAQ:EVGN) Coverage Initiated by Analysts at StockNews.com - Defense World
Evogene stock hits 52-week low at $1.18 amid market challenges - Investing.com Canada
Evogene stock hits 52-week low at $1.18 amid market challenges By Investing.com - Investing.com South Africa
Evogene (NASDAQ:EVGN) Share Price Passes Below 200 Day Moving Average – What’s Next? - Defense World
StockNews.com Initiates Coverage on Evogene (NASDAQ:EVGN) - Defense World
Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split - Marketscreener.com
StockNews.com Begins Coverage on Evogene (NASDAQ:EVGN) - Defense World
Evogene Announces Filing of Annual Report on Form 20-F - GuruFocus.com
AgPlenus Announces Discovery of a New Mode of Action for Fungici - GuruFocus.com
Evogene Ltd. Earnings Call: Growth Amid Challenges - TipRanks
Evogene Ltd. (NASDAQ:EVGN) Q4 2024 Earnings Call Transcript - Insider Monkey
Evogene price target lowered to $6 from $11.25 at Alliance Global Partners - TipRanks
Evogene: Q4 Earnings Snapshot - Barchart
Evogene Ltd to Host Earnings Call - ACCESS Newswire
Evogene Ltd. (NASDAQ:EVGN) Short Interest Up 22.1% in February - Defense World
Evogene Ltd (EVGN) Q4 2024 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance
Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025 - StreetInsider.com
Evogene Ltd. Reports Revenue Growth and Strategic Focus - TipRanks
Evogene Reports Fourth Quarter and Full Year 2024 Financial Results - The Malaysian Reserve
Earnings call transcript: Evogene Q4 2024 beats EPS forecast, misses revenue - Investing.com
Evogene Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Evogene reports Q4 EPS 6c vs. ($1.30) last year - TipRanks
Evogene reports Q4 revenue miss, shares slip By Investing.com - Investing.com South Africa
Evogene reports Q4 revenue miss, shares slip - Investing.com
Evogene earnings beat by $0.66, revenue fell short of estimates - Investing.com India
SEC Form 424B3 filed by Evogene Ltd - Quantisnow
Evogene (TSE:EVGN) Given New C$3.00 Price Target at Desjardins - Defense World
Evogene Ltd expected to post a loss of 72 cents a shareEarnings Preview - TradingView
Evogene (NASDAQ:EVGN) Now Covered by StockNews.com - Defense World
Evogene Ltd. to Host Earnings Call - ACCESS Newswire
Evogene (EVGN) Projected to Post Quarterly Earnings on Thursday - Defense World
Evogene Schedules Fourth Quarter 2024 Financial Results Release - Krishak Jagat English
Evogene Sets Date for Q4 Earnings: Key Details for Your Calendar - Stock Titan
AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease - Nasdaq
Evogene Ltd Stock (EVGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):